In the modern world, complications caused by disorders in the blood coagulation system are found in almost all areas of medicine. Thus, the development of new, more advanced drugs that can prevent pathological conditions without disrupting normal hemostasis is an urgent task. The blood coagulation factor XIIa is one of the most promising therapeutic targets for the development of anticoagulants based on its inhibitors. The initial stage of drug development is directly related to computational methods of searching for a lead compound. In this study, docking followed by quantum chemical calculations was used to search for noncovalent low-molecular-weight factor XIIa inhibitors in a focused library of druglike compounds. As a result of the study, four low-molecular-weight compounds were experimentally confirmed as factor XIIa inhibitors. Selectivity testing revealed that two of the identified factor XIIa inhibitors were selective over the coagulation factors Xa and XIa.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8876603 | PMC |
| http://dx.doi.org/10.3390/molecules27041234 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association between coagulation activity and clinical and imaging outcomes in acute ischemic stroke patients - A sub-study of the MR CLEAN NO-IV trial.
Thromb Res
January 2025
School for Cardiovascular Disease (CARIM), Maastricht University, the Netherlands; Department of Biochemistry, Cardiovascular Research Institute Maastricht, Maastricht, the Netherlands. Electronic address:
Background: The MR CLEAN NO-IV trial showed neither superiority nor noninferiority of endovascular treatment (EVT) alone compared to intravenous thrombolysis (IVT; Alteplase) before EVT in acute ischemic stroke (AIS) patients with large vessel occlusion of the anterior circulation. Although the treatment effect is largely attributable to EVT, IVT may affect hypercoagulability during AIS.
Aims: To investigate the association between activated coagulation and final infarct volume and clinical outcomes (modified Rankin Scale 3-6 and mortality 90 days post-EVT), and whether this effect is modified by IVT administration.
Hereditary angioedema (HAE) in children and adolescents: New treatment options.
Allergol Select
October 2024
Hannover Medical School (MHH), Department of Dermatology, Allergology and Venereology, Interdisciplinary Allergy Center of the MHH, Treatment Center for Hereditary Angioedema of the MHH, Hannover, Germany.
Article Synopsis
- Modern management of hereditary angioedema (HAE) emphasizes personalized treatment plans tailored to the needs of children and adolescents, as well as the severity of the disease.
- New medications have improved quality of life for HAE patients, but not all are approved for children, leading to ongoing research into alternative treatments such as those targeting bradykinin effects.
- Emerging options like oral medications, long-acting therapies, and potential gene therapy are being explored to better meet the care requirements for young patients with HAE type I and II.
Discovery of a new lead molecule to develop a novel class of human factor XIIa inhibitors.
J Thromb Thrombolysis
December 2024
Division of Basic Pharmaceutical Sciences, College of Pharmacy, Xavier University of Louisiana, New Orleans, LA, 70125, USA.
Article Synopsis
- FXIIa is a plasma protease in the contact activation pathway, and inhibiting it could lead to safer anticoagulation treatments without the bleeding risks of current options.!* -
- The study tested an amidine-containing molecule (inhibitor 1) and found it primarily inhibits human FXIIa with an IC value of ~30 µM, while showing variable selectivity against other factors involved in blood coagulation.!* -
- Inhibitor 1 effectively prolongs clotting time in plasma without significant cytotoxicity, making it a promising candidate for further development as a safer anticoagulant for thromboembolic diseases.!*
The third-generation anticoagulants: factors XI, XII, and XIII inhibitors.
Egypt Heart J
October 2024
Department of Cardiology, King George's Medical University, Shahmina Road, Chowk, Lucknow, Uttar Pradesh, 226003, India.
Article Synopsis
- * Factor XI inhibitors have shown better efficacy and safety compared to enoxaparin in reducing venous thromboembolic incidents, while factor XII inhibitors could also lower bleeding risks based on preliminary animal research.
- * Further large-scale human studies are needed to confirm the effectiveness of factor XI, XII, and XIII inhibitors in preventing thromboembolic events, as the early results for factors XII and XIII still require validation.
Long-term safety and efficacy of garadacimab for preventing hereditary angioedema attacks: Phase 3 open-label extension study.
Allergy
October 2024
Allergy, Asthma and Immunology, Department of Medicine and Pediatrics, Penn State University, Hershey, Pennsylvania, USA.
Article Synopsis
- Hereditary angioedema (HAE) is a chronic disease requiring effective long-term preventive treatments, prompting a study to evaluate the safety and efficacy of garadacimab, a new medication for HAE.
- In an interim analysis of the ongoing phase 3 VANGUARD study, involving 161 patients, most treatment-emergent adverse events (TEAEs) were mild, with injection-site reactions being the most common, and no serious complications linked to garadacimab were reported.
- The results showed a significant reduction in HAE attacks, with 60% of patients remaining attack-free, indicating that garadacimab offers a safe and effective long-term treatment option for patients with
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!